The goal of this project is to integrate data from local research, clinical and public health entities that are screening for and treating HIV infected persons. These data will be obtained in a de- identified manner, parsed and then organized into a HIPAA compliant database containing socio- demographic, geographic, reported risk behaviors and viral sequence information. The database will update itself in real-time as new HIV infections are identified, and viral sequence data will be used to map out the phylogenetic network of our local epidemic, focusing on drug using risk groups. We will utilize a background of nationwide HIV sequences obtained from publically available repositories to improve the signal in our phylogenetic structures and use Bayesian maximum likelihood analysis to build these networks in a robust manner. Finally, we will use this system to map the socio-demographic, geographic, risk behavior and phylogenetic data to locations of newly identified acute and early HIV infections. In real-time, these results will be used to identify micro-communities and sub-networks with HIV transmission associated with injection drugs or methamphetamine use, and we will use this information to direct community specific prevention resources (i.e. needle exchange, HIV testing, education, etc.) with the ultimate goal of preventing HIV transmission clusters from developing or expanding, particularly among substance using communities.
Specific Aims

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
NIH Director’s Pioneer Award (NDPA) (DP1)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1-NXR-B (06))
Program Officer
Lambert, Elizabeth
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
Internal Medicine/Medicine
Schools of Medicine
La Jolla
United States
Zip Code
Heaton, Robert K; Franklin Jr, Donald R; Deutsch, Reena et al. (2015) Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis 60:473-80
Okulicz, Jason F; Le, Tuan D; Agan, Brian K et al. (2015) Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals. JAMA Intern Med 175:88-99
Little, Susan J; Kosakovsky Pond, Sergei L; Anderson, Christy M et al. (2014) Using HIV networks to inform real time prevention interventions. PLoS One 9:e98443
Chaillon, Antoine; Gianella, Sara; Vazquez, Homero et al. (2014) Novel codon insert in HIV type 1 clade B reverse transcriptase associated with low-level viremia during antiretroviral therapy. AIDS Res Hum Retroviruses 30:165-9
Hepler, N Lance; Scheffler, Konrad; Weaver, Steven et al. (2014) IDEPI: rapid prediction of HIV-1 antibody epitopes and other phenotypic features from sequence data using a flexible machine learning platform. PLoS Comput Biol 10:e1003842
Murrell, Ben; Murrell, Daniel; Murrell, Hugh (2014) R2-equitability is satisfiable. Proc Natl Acad Sci U S A 111:E2160
Jeong, Su Jin; Kim, Min Hyung; Song, Je Eun et al. (2014) Short communication: prospective comparison of qualitative versus quantitative polymerase chain reaction for monitoring virologic treatment failure in HIV-infected patients. AIDS Res Hum Retroviruses 30:827-9
Scheffler, Konrad; Murrell, Ben; Kosakovsky Pond, Sergei L (2014) On the validity of evolutionary models with site-specific parameters. PLoS One 9:e94534
Tilghman, M W; PĂ©rez-Santiago, J; Osorio, G et al. (2014) Community HIV-1 drug resistance is associated with transmitted drug resistance. HIV Med 15:339-46
Wagner, Gabriel A; Pacold, Mary E; Kosakovsky Pond, Sergei L et al. (2014) Incidence and prevalence of intrasubtype HIV-1 dual infection in at-risk men in the United States. J Infect Dis 209:1032-8

Showing the most recent 10 out of 28 publications